文献速递胸部肿瘤放疗放疗物理与技术

胸腺与胸导管剂量对接受胸部放疗的原发性肺癌患者放射性淋巴细胞减少的剂量学影响

Dosimetric Effect of Thymus and Thoracic Duct on Radiation-Induced Lymphopenia in Patients With Primary Lung Cancer Who Received Thoracic Radiation.
PubMed 文献 · Adv Radiat Oncol · 2023-05-01

该回顾性研究纳入2015年5月至2020年2月间接受胸部放疗且有全血细胞计数数据的116例连续原发性肺癌患者,探讨胸腺与胸导管放疗剂量与放射性淋巴细胞减少的关系。结果显示淋巴细胞绝对计数变化与分期、化疗或同步放化疗、生物有效剂量、肺平均剂量、体平均剂量、免疫细胞有效剂量、胸腺平均剂量及胸导管平均剂量均显著相关(均P<.05)。岭回归模型显示胸腺与胸导管剂量与放射性淋巴细胞减少强相关,联合模型曲线下面积为0.77(P<.001),作者结论认为需进一步验证研究才能将胸腺和胸导管作为危及器官实施。

要点

  • 淋巴细胞绝对计数变化与胸腺平均剂量、胸导管平均剂量等多项剂量学因素显著相关(均P<.05)。
  • 岭回归方程:DALC=0.0063×BED+0.0172×EDIC+0.0002×MTD+0.0147×MTDD+0.2510(总体P=.00025,F=5.85)。
  • 联合模型拟合二分类终点时曲线下面积最高为0.77(P<.001),敏感度89%、特异度58%。

核心结论

  • 本研究首次证明胸腺和胸导管放疗剂量与肺癌患者放射性淋巴细胞减少强相关。
  • 作者结论指出需进一步验证研究才能将胸腺和胸导管作为危及器官实施。

研究设计与样本

  • 回顾性研究,连续纳入2015年5月至2020年2月接受胸部放疗且有全血细胞计数数据的原发性肺癌患者116例。
  • 收集年龄、性别、组织学、分期、化疗方案、放疗剂量学及淋巴细胞绝对计数等临床特征。
  • 胸腺与胸导管由一名研究者勾画以保证一致性,并由一名资深医师核对。
  • 主要终点为放疗前后淋巴细胞绝对计数差值(DALC)定义的放射性淋巴细胞减少。

主要发现

  • DALC与分期、化疗或同步放化疗、生物有效剂量、肺平均剂量、体平均剂量、免疫细胞有效剂量、胸腺平均剂量及胸导管平均剂量均显著相关(均P<.05)。
  • 岭回归显示DALC=0.0063×BED+0.0172×EDIC+0.0002×MTD+0.0147×MTDD+0.2510(总体P=.00025,F=5.85)。
  • 将DALC二分类后拟合逻辑回归模型,联合模型曲线下面积最高为0.77(P<.001)。
  • 联合模型敏感度为89%,特异度为58%。

临床怎么用

  • 原文结论未据此给出临床推荐,仅指出需进一步验证研究才能将胸腺和胸导管作为危及器官实施。

局限性

  • 原文结论指出需进一步验证研究才能将胸腺和胸导管作为危及器官实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation-induced lymphopenia is a well-recognized factor for tumor control and survival in patients with cancer. This study aimed to determine the role of radiation dose to the thymus and thoracic duct on radiation-induced lymphopenia. METHODS AND MATERIALS: Patients with primary lung cancer treated with thoracic radiation therapy between May 2015 and February 2020 with whole blood count data were eligible. Clinical characteristics, including age, gender, histology, stage, chemotherapy regimen, radiation dosimetry, and absolute lymphocyte count (ALC) were collected. The thymus and thoracic duct were contoured by one investigator for consistency and checked by one senior physician. The primary endpoint was radiation-induced decrease in lymphocytes, defined as the difference in ALC (DALC) before and after radiation therapy. RESULTS: The data of a total of 116 consecutive patients were retrospectively retrieved. Significant correlations were found between DALC and several clinical factors. These factors include stage, chemotherapy or concurrent chemoradiation, biologically effective dose (BED), mean lung dose, mean body dose, effective dose to immune cells (EDIC), mean thymus dose (MTD), and mean thoracic duct dose (MTDD) (all P < .05). Ridge regression showed that DALC = 0.0063 × BED + 0.0172 × EDIC + 0.0002 × MTD + 0.0147 × MTDD + 0.2510 (overall P = .00025 and F = 5.85). The combination model has the highest area under the curve of 0.77 (P < .001) when fitting the logistic regression model on DALC categorized as binary endpoint. The sensitivity and specificity of the combined model were 89% and 58%, respectively. CONCLUSIONS: This study demonstrated for the first time that radiation doses to the thymus and thoracic duct are strongly associated with radiation-induced lymphopenia patients with lung cancer. Further validation studies are needed to implement thymus and thoracic duct as organs at risk.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Yang L, Li H, et al. Dosimetric Effect of Thymus and Thoracic Duct on Radiation-Induced Lymphopenia in Patients With Primary Lung Cancer Who Received Thoracic Radiation. Adv Radiat Oncol. 2023. PMID: 38047216. doi:10.1016/j.adro.2023.101260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。